Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Mean Change in Macular Thickness Between Intravitreal Bevacizumab and Posterior Sub-Tenon Triamcinolone Acetonide for Diabetic Macular Edema

NCT07933250 is registered in ClinicalTrials.gov with Muhammad Aamir Latif as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Mean Change in Macular Thickness Between Intravitreal Bevacizumab and Posterior Sub-Tenon Triamcinolone Acetonide for Diabetic Macular Edema
Lead sponsor
Muhammad Aamir Latif
Phase
Not applicable
Overall status
Completed
Start date
October 1, 2025
Completion date
June 30, 2026
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema

Arms

As registered; 2 arms.

  • Bevacizumab-Group ExperimentalBevacizumab Intravitreal Injection

    Patients received an intravitreal injection of bevacizumab 1.25 mg/0.05 mL through the pars plana 3.5-4 mm posterior to the limbus under local anesthesia.

  • Triamcinolone acetonide-Group ExperimentalTriamcinolone Acetonide Injection

    Patients received a posterior sub-Tenon injection of triamcinolone acetonide 1.25 mg under aseptic conditions. The triamcinolone was drawn into a 1-mL syringe and administered using a 26-gauge, 5/8-inch sharp-tipped needle, which was advanced to facilitate deposition within the posterior sub-Tenon space.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Central Macular Thickness 30 days

    Change in CMT, measured in micrometers (μm), was calculated as baseline CMT minus CMT measured one month after treatment. A positive value indicated a reduction in CMT, whereas a negative value indicated an increase in CMT.

Lead sponsor's other trials

Muhammad Aamir Latif, most recent start first.